Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ron who wrote (1132)	4/13/2000 7:46:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1386

The FDA accurately reasons that hospitals/practitioners will ultimately buy and use HU211 on the basis of believing that it will improve patient outcome. So they want Pharmos to prove that such is actually the case, rather than using a surrogate endpoint. I am not defending the FDA, I personally believe that the connection between ICP and clinical outcome is pretty clear, and the fact that ICP is so much more easily measured than vaguely defined 'clinical outcome' makes it a much simpler trial to run. But that's the CNS Division of the FDA for you. They will never let little things like patient care stand in the way of scientific rigor. NeuroInvestment (www.neuroinvestment.com)